GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » FCF Yield %

CUE (Cue Biopharma) FCF Yield % : -64.36 (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cue Biopharma's Trailing 12-Month Free Cash Flow is $-38.32 Mil, and Market Cap is $59.55 Mil. Therefore, Cue Biopharma's FCF Yield % for today is -64.36%.

The historical rank and industry rank for Cue Biopharma's FCF Yield % or its related term are showing as below:

CUE' s FCF Yield % Range Over the Past 10 Years
Min: -146.8   Med: -18.87   Max: -4.16
Current: -64.36


During the past 9 years, the highest FCF Yield % of Cue Biopharma was -4.16%. The lowest was -146.80%. And the median was -18.87%.

CUE's FCF Yield % is ranked worse than
76.64% of 1507 companies
in the Biotechnology industry
Industry Median: -13.02 vs CUE: -64.36

Cue Biopharma's FCF Margin % for the quarter that ended in Sep. 2024 was -225.60%.


Cue Biopharma FCF Yield % Historical Data

The historical data trend for Cue Biopharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma FCF Yield % Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only -7.31 -8.71 -10.91 -34.22 -32.06

Cue Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.06 -35.16 -42.81 -66.32 -66.03

Competitive Comparison of Cue Biopharma's FCF Yield %

For the Biotechnology subindustry, Cue Biopharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's FCF Yield % falls into.



Cue Biopharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cue Biopharma's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-39.961 / 124.647864
=-32.06%

Cue Biopharma's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-7.526 * 4 / 45.58927044
=-66.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cue Biopharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Cue Biopharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Executives
Anish Suri officer: President and CSO 40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri director, officer: CEO 40 GUEST STREET, BOSTON MA 02135
Pamela Garzone director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti officer: Chief Medical Officer C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn officer: Chief Business Officer C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar officer: CFO 40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta officer: Chief Medical Officer C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin officer: SVP, General Counsel and Sec 40 GUEST STREET, BOSTON MA 02135
Tamar D Howson director
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll director